Arcadia Biosciences, Inc.
RKDA
$1.12
$0.076.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -30.80% | -10.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -30.80% | -10.52% | |||
| Cost of Revenue | -19.80% | 6.12% | |||
| Gross Profit | -54.07% | -32.80% | |||
| SG&A Expenses | -0.19% | -26.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.25% | -16.98% | |||
| Operating Income | -19.36% | 23.25% | |||
| Income Before Tax | -255.14% | 119.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -256.07% | 119.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -256.07% | 119.20% | |||
| EBIT | -19.36% | 23.25% | |||
| EBITDA | -19.39% | 22.61% | |||
| EPS Basic | -255.53% | 119.20% | |||
| Normalized Basic EPS | -254.61% | 115.68% | |||
| EPS Diluted | -257.68% | 119.01% | |||
| Normalized Diluted EPS | -255.13% | 129.73% | |||
| Average Basic Shares Outstanding | 0.34% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.00% | -47.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||